Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | RECQL | P46063 | 2/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27657411 | 0.86 | S1PR1 (0.61) | SMN1; SMN2TSHRRECQLS1PR1LMNA | |
| SCHEMBL7152014 | 0.81 | SIRT2 (0.68) | SMN1; SMN2TSHRLMNAHTTRAB9A | |
| SCHEMBL4521919 | 0.79 | NOTUM (0.67) | SMN1; SMN2TSHRRECQLS1PR1LMNA | |
| SCHEMBL4522502 | 0.79 | NOTUM (0.71) | SMN1; SMN2TSHRRECQLS1PR1LMNA | |
| SCHEMBL4288756 | 0.79 | S1PR1 (0.61) | SMN1; SMN2TSHRRECQLS1PR1LMNA | |
| SCHEMBL7148635 | 0.78 | SIRT2 (0.70) | SMN1; SMN2TSHRLMNAHTTRAB9A | |
| SCHEMBL4036650 | 0.78 | TSHR (0.72) | SMN1; SMN2TSHRRECQLS1PR1LMNA | |
| SCHEMBL5204786 | 0.75 | ALDH1A1 (0.62) | SMN1; SMN2TSHRRECQLS1PR1LMNA | |
| SCHEMBL5717742 | 0.75 | ALDH1A1 (0.79) | SMN1; SMN2TSHRRECQLS1PR1LMNA | |
| SCHEMBL12092543 | 0.75 | HTT (0.61) | SMN1; SMN2TSHRRECQLS1PR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0952157-B1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | PFIZER PROD INC (US) | 2003-06-18 | — | — | EP | claimed |
| US-6482801-B2 | THERAPY FOR BACTERIAL OR PROTOZOA INFECTIONS | PFIZER INC. | 2002-11-19 | — | — | US | claimed |
| US-20010016574-A1 | 9a,11b-dehydro derivatives of 9-oxime-3-keto-6-O- methylerythromycin | WU YONG-JIN (US) | 2001-08-23 | — | — | US | claimed |
| US-6262030-B1 | Erythromycin derivatives | PFIZER INC. | 2001-07-17 | — | — | US | claimed |
| US-6248719-B1 | Tricyclic 3-keto derivatives of 6-O-methylerthromycin | PFIZER INC | 2001-06-19 | — | — | US | claimed |
| WO-1999062920-A1 | TRICYCLIC 3-KETO DERIVATIVES OF 6-O-METHYLERYTHROMYCIN | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | claimed |
| EP-0952157-A1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | Pfizer Products Inc. (US) | 1999-10-27 | — | — | EP | claimed |
| EP-0952157-B1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | PFIZER PROD INC (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6482801-B2 | THERAPY FOR BACTERIAL OR PROTOZOA INFECTIONS | PFIZER INC. | 2002-11-19 | — | — | US | disclosed |
| US-20010016574-A1 | 9a,11b-dehydro derivatives of 9-oxime-3-keto-6-O- methylerythromycin | WU YONG-JIN (US) | 2001-08-23 | — | — | US | disclosed |
| US-6262030-B1 | Erythromycin derivatives | PFIZER INC. | 2001-07-17 | — | — | US | disclosed |
| US-6248719-B1 | Tricyclic 3-keto derivatives of 6-O-methylerthromycin | PFIZER INC | 2001-06-19 | — | — | US | disclosed |
| WO-1999062920-A1 | TRICYCLIC 3-KETO DERIVATIVES OF 6-O-METHYLERYTHROMYCIN | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0952157-A1 | 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin | Pfizer Products Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016574-A1 | 9a,11b-dehydro derivatives of 9-oxime-3-keto-6-O- methylerythromycin | CYP7A1, HSD17B7, CYP51A1 | SMN1; SMN2 2559/4885TSHR 3121/4885RECQL 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.